Foghorn Therapeutics, Inc. (FHTX)
1.72
-0.06
(-3.37%)
USD |
NASDAQ |
Nov 20, 16:00
1.72
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Research and Development Expense (TTM) : 76.22M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 76.22M |
| June 30, 2026 | 76.69M |
| March 31, 2026 | 79.26M |
| December 31, 2025 | 82.04M |
| September 30, 2025 | 80.54M |
| June 30, 2025 | 85.43M |
| March 31, 2025 | 87.53M |
| December 31, 2024 | 91.43M |
| September 30, 2024 | 95.04M |
| June 30, 2024 | 96.44M |
| March 31, 2024 | 101.81M |
| December 31, 2023 | 106.24M |
| Date | Value |
|---|---|
| September 30, 2023 | 110.24M |
| June 30, 2023 | 110.94M |
| March 31, 2023 | 107.73M |
| December 31, 2022 | 102.30M |
| September 30, 2022 | 96.59M |
| June 30, 2022 | 90.14M |
| March 31, 2022 | 82.84M |
| December 31, 2021 | 77.10M |
| September 30, 2021 | 71.35M |
| June 30, 2021 | 67.83M |
| March 31, 2021 | 63.35M |
| December 31, 2020 | 56.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anavex Life Sciences Corp. | 11.44M |
| Vaxcyte, Inc. | 1.093B |
| Connect Biopharma Holdings Ltd. | 55.37M |
| Caribou Biosciences, Inc. | 84.72M |
| Oncolytics Biotech, Inc. | 13.18M |